News

AC Immune amends agreement with Lilly to develop potential Alzheimer’s treatment

Apr 16, 2026 | News, Research

The agreement covers the development of new lead tau morphomer candidates

EMA’s PRIME scheme launches three major new features

Apr 15, 2026 | News, Healthcare

The scheme supports the development of treatments targeting unmet medical needs in the EU

Annovis partners with NeuroRPM on new AI platform to track Parkinson’s symptoms

Apr 14, 2026 | News, Healthcare

The platform will passively collect data to understand treatment responses in everyday life

START partners with Trialing to expand patient access to oncology clinical trials across Europe

Apr 14, 2026 | News, Healthcare

The collaboration will combine START’s trial network and Trialing’s physician network

Bristol Myers Squibb evolves and expands multiple myeloma programme

Apr 13, 2026 | News, Research

Created in 2016, the Standing in the Gaap programme aims to advance more equitable care

One-carbon Therapeutics collaborates with Tempus in cancer treatment

Apr 13, 2026 | News, Research

The treatment is currently being evaluated in a phase 1/2 multicentre clinical study

Lilly to acquire Centessa in deal worth up to $7.8bn

Apr 10, 2026 | News, Sales

The companies aim to advance treatments for narcolepsy and other sleep-wake disorders

Biogen to acquire Apellis in $5.6bn deal

Apr 9, 2026 | News, Sales

The deal will enhance Biogen’s growth portfolio in immunology and rare disease

Gilead to acquire Tubulis for up to $5bn

Apr 8, 2026 | News, Sales

The acquisition builds on Gilead’s oncology pipeline, focused on addressing areas of high unmet need

Lilly’s Foundayo approved by US FDA as oral GLP-1 for weight loss

Apr 7, 2026 | News, Regulatory

Taken at any time of the day, the oral GLP-1 is the only pill to have no food or water restrictions

Roche opens new Swiss Institute of Human Biology research facility

Apr 2, 2026 | News, Research

The new building is part of a 1.5bn euro site investment

Novartis to acquire Excellergy in deal worth up to $2bn

Apr 1, 2026 | News, Sales

Exl-111, a potential treatment included in the deal, is a central factor in many allergic diseases

AC Immune amends agreement with Lilly to develop potential Alzheimer’s treatment

EMA’s PRIME scheme launches three major new features

Annovis partners with NeuroRPM on new AI platform to track Parkinson’s symptoms

START partners with Trialing to expand patient access to oncology clinical trials across Europe

Bristol Myers Squibb evolves and expands multiple myeloma programme

One-carbon Therapeutics collaborates with Tempus in cancer treatment

Lilly to acquire Centessa in deal worth up to $7.8bn

Biogen to acquire Apellis in $5.6bn deal

Gilead to acquire Tubulis for up to $5bn

Lilly’s Foundayo approved by US FDA as oral GLP-1 for weight loss

Roche opens new Swiss Institute of Human Biology research facility

Novartis to acquire Excellergy in deal worth up to $2bn

Latest content

Latest intelligence

Quick links